Skip to main content

Month: April 2020

Borqs Technologies, Inc. receives up to US$150 million Line of Credit Offer For serving Borqs large customer pre-orders forecasted at over US$100 million

SANTA CLARA, Calif., April 13, 2020 (GLOBE NEWSWIRE) — Borqs Technologies, Inc. (Nasdaq: BRQS), (the “Company”, or “Borqs”), a global leader in embedded software and products for the Internet of Things (IoT) industry, today announced that the Company has received a line of credit offer of up to US$150 million from a financing group for working capital needs for the Company’s customer pre-orders forecasted at over US$100 million.  The orders are for mobile and IoT devices with Borqs’ embedded software scheduled for delivery beginning in the 2nd quarter of 2020 and extending into the year 2021.The available funds will be primarily used for Borqs development of customized hardware products, integrated with the Company’s propriety software, to major international customers. Such products include IoT and mobile terminal devices for the...

Continue reading

HEXO Corp. Closes $46 Million Underwritten Public Offering

OTTAWA, April 13, 2020 (GLOBE NEWSWIRE) — HEXO Corp. (“HEXO”, or the “Company”) (TSX: HEXO; NYSE: HEXO) today announced the closing of its previously announced underwritten public offering (the “Offering”) for total gross proceeds to the Company of approximately C$46 million. The Company sold 59,800,000 units of the Company (the “Units”) at a price of C$0.77 per Unit under the Offering, including 7,800,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.Each Unit is comprised of one common share of the Company and one common share purchase warrant of the Company. Each warrant is exercisable to acquire one common share of the Company for a period of 5 years following the closing date of the Offering at an exercise price of C$0.96 per share, subject to adjustment in certain events.Canaccord Genuity...

Continue reading

HEXO Corp. clôture un placement public par prise ferme de 46 millions de dollars

OTTAWA, 13 avr. 2020 (GLOBE NEWSWIRE) — HEXO Corp. (« HEXO », ou la « Société ») (TSX : HEXO ; NYSE : HEXO) a annoncé aujourd’hui la clôture de son placement public par prise ferme précédemment publié (le « placement »), pour un produit brut total pour la Société d’environ 46 million de dollars canadiens. La Société a vendu 59 800 000 unités de la Société (les « unités ») au prix de 0,77 dollars canadiens par unité dans le cadre du placement, y compris 7 800 000 unités vendues en vertu de l’exercice intégral par les preneurs fermes de leur option de surallocation.Chaque unité est composée d’une action ordinaire de la Société et d’un bon de souscription d’action ordinaire de la Société. Chaque bon de souscription peut être exercé pour acquérir une action ordinaire de la Société pendant une période de 5 ans...

Continue reading

Laureate Education Announces Date of First Quarter 2020 Earnings Release and Conference Call

BALTIMORE, April 13, 2020 (GLOBE NEWSWIRE) — Laureate Education, Inc. (NASDAQ: LAUR) plans to release results for the quarter ended March 31, 2020, on Thursday, May 7, 2020, before the stock market opens. Following the release, the Company will host a telephone conference call with investors and analysts at 8:30 a.m. ET to discuss the first quarter results and the Company’s business outlook.Interested parties are invited to listen to the earnings conference call by dialing 1-855-307-2849 (for U.S.- based callers), or 1-703-639-1262 (for international callers), and requesting to join the Laureate Education conference call, conference ID 8368663. Replays of the entire call will be available through May 14, 2020 at 1-855-859-2056 (for U.S.- based callers) and at 1-404-537-3406 (internationally), conference ID 8368663.The webcast...

Continue reading

Jessica Brennan Joins Onex as Head of Client and Product Solutions

All amounts in U.S. dollars unless otherwise statedTORONTO, April 13, 2020 (GLOBE NEWSWIRE) — Onex Corporation (“Onex”) (TSX: ONEX) announced today that Jessica Brennan will be joining as Managing Director, Head of Client and Product Solutions. Jessica will be based in Onex’ New York office. In this new firm-wide role, Ms. Brennan will oversee new fund formation, investor relations and fundraising and client product solutions across the entire Onex platform.     Gerry Schwartz, Onex’ Chairman and Chief Executive Officer, said, “Onex is proud of the close relationships maintained with its investors. We are excited that Jessica is joining Onex and will help position the firm for future growth.”Ms. Brennan stated, “I am delighted to join Onex in this next and exciting growth phase. It is a firm with a remarkable history and a distinguished...

Continue reading

89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor Agonism

– Closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled and delays initiation of its SHTG trial due to the COVID-19 pandemic; Reaffirms guidance for NASH trial topline data in 2H20 –– BIO89-100 demonstrated low nanomolar potency against FGF receptors 1c, 2c and 3c similar to recombinant human FGF21 (rhFGF21) –SAN FRANCISCO, April 13, 2020 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it closed enrollment in its Phase 1b/2a trial for nonalcoholic steatohepatitis (NASH) with 98% of patients enrolled and has delayed initiation of its severe hypertriglyceridemia (SHTG) trial due to the ongoing...

Continue reading

La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Emergency Medical Program in Patients with Septic Shock Due to COVID-19 at CHIREC Delta Hospital, Brussels, Belgium

SAN DIEGO, April 13, 2020 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing GIAPREZA™ (angiotensin II) for an emergency medical  program in patients with septic shock due to COVID-19 at the Centre Hospitalier Interrégional Edith Cavell (CHIREC) Delta Hospital in Brussels, Belgium. GIAPREZA is being made available for emergency medical use based on a request from Professor Daniel De Backer, M.D., Head, Department of Intensive Care, CHIREC Delta Hospital in Brussels, Belgium. According to Belgian law, authorized medicines can be made available prior to commercial availability in order to fulfill special patient needs. GIAPREZA...

Continue reading

Alimera Sciences Pre-Announces Expected Top Line Revenue for Q1 2020 and Provides COVID-19 Business Update

ATLANTA, April 13, 2020 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announces top-line revenue guidance for the quarter ended March 31, 2020.Alimera expects to report consolidated net revenue for the first quarter of 2020 exceeding $14 million, which compares to $12.9 million in the first quarter of 2019. Additionally, the Company strengthened its balance sheet during the quarter with both an additional draw of $2.5 million under its $45 million term loan agreement with its current lenders, investment affiliates managed by Solar Capital Partners, LLC, and cash flow generation from operations. Alimera expects to report cash on hand...

Continue reading

Overstock Announces Filing of Prospectus Supplements

SALT LAKE CITY, April 13, 2020 (GLOBE NEWSWIRE) — Overstock.com, Inc. (NASDAQ:OSTK) announces the filing today of a prospectus supplement in connection with its dividend of Digital Voting Series A-1 Preferred Stock with the Securities and Exchange Commission (SEC). This filing completes the registration process for the Digital Voting Series A-1 Preferred shares (OSTKO) with the SEC in advance of the company’s dividend issuance. No further regulatory filings are required in connection with the Series A-1 Preferred dividend.“This filing is the next step in preparing for the issuance of our historic digital dividend,” said Overstock CEO Jonathan Johnson. “The ability to issue our shareholders a dividend using the technology we believe will backbone the next generation of capital markets is a significant opportunity for Overstock, tZERO,...

Continue reading

Zoom Users Turn to StrikeForce’s Privacy Protection Software to Protect Video Conferencing & Confidential Information

EDISON, N.J., April 13, 2020 (GLOBE NEWSWIRE) — StrikeForce Technologies, Inc. (OTC PINK: SFOR), announces that Zoom users are installing Strikeforce’s Privacy Protection Suite, aka GuardedID & MobileTrust, to protect their Zoom video conferencing sessions and stored confidential information.“The COVID-19 pandemic has drastically changed how people and businesses now communicate,”  says Mark L. Kay, CEO of StrikeForce. “Video conferencing services i.e. Zoom, Webex, Skype, GotoMeeting & join.me have emerged as the defacto-replacement for face-to-face meetings. However, hackers are now targeting these users by leveraging pandemic news articles, emails, phishing, vishing & texting schemes, all designed to trick a remote worker to silently download keylogging malware onto their computer, or, mobile device,” says Kay.“That’s...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.